Drug Discovery Informatics Market by Mode (Outsourced Informatics and In-House Informatics), by Services (Docking and Modular Modeling): Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 - 2021

Description

The report covers forecast and analysis for the drug discovery informatics market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based revenue (USD million). The study includes drivers and restraints for the market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the drug discovery informatics market on a global level.

In order to give the users of this report a comprehensive view on the drug discovery informatics market, we have included a detailed competitive scenario and model portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter’s five forces model for the drug discovery informatics market has also been included. The study encompasses a market attractiveness analysis, wherein type segments are benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view on the drug discovery informatics market by segmenting the market based on mode, services, and region. Based on mode, the drug discovery informatics market can be segmented into outsourced informatics and in-house informatics. The major services covered under this study include docking and modular modeling. All the segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America and Middle East and Africa with its further bifurcation into major countries including U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, New Zealand, Egypt, Argentina and Brazil.

The report covers detailed competitive outlook including company profiles of the key participants operating in the global market. The key players of ChemAxon, GVK Biosciences, Jubilant Biosys, Selvita, Certara, Infosys, Albany Molecular Research Inc., Boehringer Ingelheim GmBh, DiscoverX, Charles River Laboratories, Covance, Collaborative Drug Discovery Inc., Novo Informatics, UCB, Evotec among others.

This report segments the drug discovery informatics market as follows:

Drug Discovery Informatics Market: Mode Segment Analysis

• Outsourced Informatics
• In-House Informatics

Drug Discovery Informatics Market: Services Segment Analysis

• Docking
• Modular Modeling

Drug Discovery Informatics Market: Regional Segment Analysis

• North America
  • US 
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
• The Middle East and Africa
  • South Africa
  • Egypt

Table Of Content

• Chapter 1. Preface
  • 1.1. Report Description and Scope
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology
• Chapter 2. Executive Summary
  • 2.1. Drug Discovery Informatics Market, 2015 - 2021 (USD Billion)
  • 2.2. Drug Discovery Informatics Market: Snapshot
• Chapter 3. Drug Discovery Informatics Market – Industry Analysis
  • 3.1. Drug Discovery Informatics Market: Market Dynamics
  • 3.2. Market Drivers
    • 3.2.1. Rising R&D expenditure
    • 3.2.2. Increasing focus on drug discovery
  • 3.3. Restraints
    • 3.3.1. Scarcity of skilled professionals
    • 3.3.2. High pricing
  • 3.4. Opportunity
    • 3.4.1. Technological advancements
  • 3.5. Porter’s Five Forces Analysis
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. Market attractiveness analysis By Mode
    • 3.6.2. Market attractiveness analysis By Services
    • 3.6.3. Market attractiveness analysis by Region
• Chapter 4. Drug Discovery Informatics Market– Competitive Landscape
  • 4.1. Company market share analysis
    • 4.1.1. Global Drug Discovery Informatics Market: company market share, 2018
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New Product launches
    • 4.2.3. Agreements, partnerships, cullaborations and joint ventures
    • 4.2.4. Research and development and Regional expansion
  • 4.3. Price trend analysis
• Chapter 5. Global Drug Discovery Informatics Market –Mode Analysis
  • 5.1. Global Drug Discovery Informatics Market overview: By Mode
    • 5.1.1. Global Drug Discovery Informatics Market share, By Mode, 2015 and 2021
  • 5.2. Outsourced Informatics
    • 5.2.1. Global Drug Discovery Informatics Market by Outsourced Informatics, 2015 - 2021 (USD Billion)
  • 5.3. In-House Informatics
    • 5.3.1. Global Drug Discovery Informatics Market by In-House Informatics, 2015 - 2021 (USD Billion)
• Chapter 6. Global Drug Discovery Informatics Market –Services Analysis
  • 6.1. Global Drug Discovery Informatics Market overview: By Services
    • 6.1.1. Global Drug Discovery Informatics Market share, By Services, 2015 and 2021
  • 6.2. Docking
    • 6.2.1. Global Drug Discovery Informatics Market By Docking, 2015 - 2021 (USD Billion)
  • 6.3. Modular Modeling
    • 6.3.1. Global Drug Discovery Informatics Market By Modular Modeling, 2015 - 2021 (USD Billion)
• Chapter 7. Global Drug Discovery Informatics Market - Regional Analysis
  • 7.1. Global Drug Discovery Informatics Market overview: by Region
    • 7.1.1. Global Drug Discovery Informatics Market share, by Region, 2015 and 2021
  • 7.2. North America
    • 7.2.1. North America Drug Discovery Informatics Market, 2015 - 2021 (USD Billion)
    • 7.2.2. North America Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
    • 7.2.3. North America Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
    • 7.2.4. U.S.
      • 7.2.4.1. U.S. Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
      • 7.2.4.2. U.S. Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
    • 7.2.5. Rest of North America
      • 7.2.5.1. Rest of North America Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
      • 7.2.5.2. Rest of North America Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Drug Discovery Informatics Market, 2015 - 2021 (USD Billion)
    • 7.3.2. Europe Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
    • 7.3.3. Europe Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
    • 7.3.4. UK
      • 7.3.4.1. U.K. Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
      • 7.3.4.2. U.K. Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
    • 7.3.5. France
      • 7.3.5.1. France Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
      • 7.3.5.2. France Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
    • 7.3.6. Germany
      • 7.3.6.1. Germany Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
      • 7.3.6.2. Germany Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
    • 7.3.7. Rest of Europe
      • 7.3.7.1. Rest of Europe Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
      • 7.3.7.2. Rest of Europe Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Drug Discovery Informatics Market, 2015 - 2021 (USD Billion)
    • 7.4.2. Asia Pacific Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
    • 7.4.3. Asia Pacific Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
    • 7.4.4. China
      • 7.4.4.1. China Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
      • 7.4.4.2. China Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
    • 7.4.5. Japan
      • 7.4.5.1. Japan Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
      • 7.4.5.2. Japan Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
    • 7.4.6. India
      • 7.4.6.1. India Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
      • 7.4.6.2. India Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
    • 7.4.7. Rest of Asia Pacific
      • 7.4.7.1. Rest of Asia Pacific Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
      • 7.4.7.2. Rest of Asia Pacific Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Drug Discovery Informatics Market, 2015 - 2021 (USD Billion)
    • 7.5.2. Latin America Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
    • 7.5.3. Latin America Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
    • 7.5.4. Brazil
      • 7.5.4.1. Brazil Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
      • 7.5.4.2. Brazil Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
    • 7.5.5. Rest of Latin America
      • 7.5.5.1. Rest of Latin America Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
      • 7.5.5.2. Rest of Latin America Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
  • 7.6. The Middle East and Africa
    • 7.6.1. The Middle East and Africa Drug Discovery Informatics Market, 2015 - 2021 (USD Billion)
    • 7.6.2. The Middle East and Africa Drug Discovery Informatics Market revenue, By Mode,2015 - 2021 (USD Billion)
    • 7.6.3. The Middle East and Africa Drug Discovery Informatics Market revenue, By Services, 2015 - 2021 (USD Billion)
• Chapter 8. Company Profiles
  • 8.1. ChemAxon
    • 8.1.1. Overview
    • 8.1.2. Financials
    • 8.1.3. Mode Portfolio
    • 8.1.4. Business Strategy
    • 8.1.5. Recent Developments
  • 8.2. GVK Biosciences
    • 8.2.1. Overview
    • 8.2.2. Financials
    • 8.2.3. Mode Portfolio
    • 8.2.4. Business Strategy
    • 8.2.5. Recent Developments
  • 8.3. Jubilant Biosys
    • 8.3.1. Overview
    • 8.3.2. Financials
    • 8.3.3. Mode Portfolio
    • 8.3.4. Business Strategy
    • 8.3.5. Recent Developments
  • 8.4. Selvita
    • 8.4.1. Overview
    • 8.4.2. Financials
    • 8.4.3. Mode Portfolio
    • 8.4.4. Business Strategy
    • 8.4.5. Recent Developments
  • 8.5. Certara
    • 8.5.1. Overview
    • 8.5.2. Financials
    • 8.5.3. Mode Portfolio
    • 8.5.4. Business Strategy
    • 8.5.5. Recent Development
  • 8.6. Infosys
    • 8.6.1. Overview
    • 8.6.2. Financials
    • 8.6.3. Mode Portfolio
    • 8.6.4. Business Strategy
    • 8.6.5. Recent Development
  • 8.7. Albany Molecular Research Inc.
    • 8.7.1. Overview
    • 8.7.2. Financials
    • 8.7.3. Mode Portfolio
    • 8.7.4. Business Strategy
    • 8.7.5. Recent Development
  • 8.8. Boehringer Ingelheim GmBh
    • 8.8.1. Overview
    • 8.8.2. Financials
    • 8.8.3. Mode Portfolio
    • 8.8.4. Business Strategy
    • 8.8.5. Recent Development
  • 8.9. DiscoverX
    • 8.9.1. Overview
    • 8.9.2. Financials
    • 8.9.3. Mode Portfolio
    • 8.9.4. Business Strategy
    • 8.9.5. Recent Development
  • 8.10. Charles River Laboratories
    • 8.10.1. Overview
    • 8.10.2. Financials
    • 8.10.3. Mode Portfolio
    • 8.10.4. Business Strategy
    • 8.10.5. Recent Development
  • 8.11. Covance
    • 8.11.1. Overview
    • 8.11.2. Financials
    • 8.11.3. Mode Portfolio
    • 8.11.4. Business Strategy
    • 8.11.5. Recent Development
  • 8.12. Cullaborative Drug Discovery Inc.
    • 8.12.1. Overview
    • 8.12.2. Financials
    • 8.12.3. Mode Portfolio
    • 8.12.4. Business Strategy
    • 8.12.5. Recent Development
  • 8.13. Novo Informatics
    • 8.13.1. Overview
    • 8.13.2. Financials
    • 8.13.3. Mode Portfolio
    • 8.13.4. Business Strategy
    • 8.13.5. Recent Development
  • 8.14. UCB
    • 8.14.1. Overview
    • 8.14.2. Financials
    • 8.14.3. Mode Portfolio
    • 8.14.4. Business Strategy
    • 8.14.5. Recent Development
  • 8.15. Evotec
    • 8.15.1. Overview
    • 8.15.2. Financials
    • 8.15.3. Mode Portfolio
    • 8.15.4. Business Strategy
    • 8.15.5. Recent Development

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Drug Discovery Informatics market. Zion Research has collected and analyzed key data belong to the global Drug Discovery Informatics market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducing a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Drug Discovery Informatics across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Drug Discovery Informatics industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

• Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
• Helps in validating and strengthening the secondary research findings
• Further, develops the analysis team’s expertise and market understanding
• Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

• Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
• Purchasing managers, technical personnel, distributors and resellers
• Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

• Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
• IDC and other relevant magazines
• Internal and external proprietary databases, and relevant patent and regulatory databases
• National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Drug Discovery Informatics market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

• Demographic data: Population split by segments
• Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
• Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
• Data is then cross-checked by an expert panel.

Free Analysis

Drug discovery is a havoc process that requires much time to invent the drug for any disease or disorder. During the invention procedure, it generates the huge amount of data which can be further utilized while clinical study or other during other invention. This data can be stored manipulate and retrieve through the drug discovery analytics.

Drug discovery analytics is a special kind of application or software which can be stores and retrieves the structured and unstructured data that is generated while drug discovery process. The drug discovery analytics helps to reduce the cost of treatment and it provides efficient and accurate data. This kind of data is utilized further by R&D, pharmaceutical, biotech companies and physicians. 

The drug discovery informatics market is primarily driven by rising demand for computational technology in the medical industry. Use of computational technology offers the fastest and accurate data to the end-users. However, critical attributes of data evaluation in drug discovery informatics is a major restraint that is likely to impede the growth of the market. Nonetheless, adoption of computational technology in emerging economies is expected to open new opportunities for market participants in near future.

Based on mode, the global drug discovery informatics market is segmented into outsourced informatics and in-house informatics. Among two, in-house informatics was leading mode segment. It accounted more than 50.0% share of the overall revenue generated by global drug discovery informatics market in 2015.  Moreover, the outsourced informatics is expected to have significant growth during the years to come.

Docking, modular modeling, and others are the key services of global drug discovery informatics market. Modular modeling was the foremost service segment that accounted for over 22.0% share of the entire market in 2015. Furthermore, it also expected to grow at a moderate pace due to growing adoption of analytics in the medical industry across the globe.

With the largest share, North America was the dominating regional market for drug discovery informatics in 2015. Asia Pacific is foreseen as a fastest growing region for drug discovery informatics market due to emerging pharmaceutical industries coupled with rising prevalence of cancer disease in China and India. Furthermore, Europe is likely to witness a moderate growth within the forecast period.

Some of the key players involved in global drug discovery informatics market include ChemAxon, GVK Biosciences, Jubilant Biosys, Selvita, Certara, Infosys, Albany Molecular Research Inc., Boehringer Ingelheim GmBh, DiscoverX, Charles River Laboratories, Covance, Collaborative Drug Discovery Inc., Novo Informatics, UCB, Evotec among others.